GlobeNewswire: Intercept Pharmaceuticals, Inc. Contains the last 10 of 304 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T01:40:22ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/29/2837979/0/en/Intercept-Announces-FDA-Acceptance-of-Supplemental-New-Drug-Application-for-Ocaliva-obeticholic-acid-for-the-Treatment-of-PBC.html?f=22&fvtc=4&fvtv=17531Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC 2024-02-29T13:30:00Z<![CDATA[MORRISTOWN, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Ocaliva for the treatment of individuals with primary biliary cholangitis (PBC). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 15, 2024. In this communication, the agency informed Intercept that they are planning to hold an Advisory Committee meeting to discuss the application.]]>https://www.globenewswire.com/news-release/2023/11/13/2779021/0/en/Intercept-Announces-New-Phase-2-Data-Showing-Significant-Impact-of-OCA-Bezafibrate-Combination-on-Normalization-of-Multiple-Key-Biomarkers-of-PBC-Induced-Liver-Damage-at-AASLD-The-.html?f=22&fvtc=4&fvtv=17531Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 20232023-11-13T13:00:00Z<![CDATA[Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks]]>https://www.globenewswire.com/news-release/2023/11/10/2778265/0/en/Intercept-Announces-New-Findings-from-Long-term-Extension-of-Landmark-POISE-Trial-in-PBC-Showing-Importance-of-Biomarkers-Beyond-ALP-at-AASLD-The-Liver-Meeting-2023.html?f=22&fvtc=4&fvtv=17531Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 20232023-11-10T13:00:00Z<![CDATA[New analysis demonstrates the impact of OCA on achievement of GGT <3.2×ULN and ALP <1.5×ULN]]>https://www.globenewswire.com/news-release/2023/11/08/2776377/0/en/Alfasigma-completes-acquisition-of-Intercept-Pharmaceuticals-Inc.html?f=22&fvtc=4&fvtv=17531Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.2023-11-08T14:13:49Z<![CDATA[BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.]]>https://www.globenewswire.com/news-release/2023/09/26/2749452/0/en/Alfasigma-to-Acquire-Intercept-Pharmaceuticals-for-19-00-per-Share-in-Cash-Expanding-the-Global-Footprint-of-Alfasigma-Via-a-Leader-in-Rare-and-Serious-Liver-Diseases.html?f=22&fvtc=4&fvtv=17531Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases2023-09-26T12:00:00Z<![CDATA[BOLOGNA, Italy and MORRISTOWN, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A (“Alfasigma”), one of Italy's leading pharmaceutical companies, and Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT, “Intercept”), a leading biopharmaceutical company in rare and serious liver diseases, today announced that they have entered into a definitive merger agreement under which Alfasigma has agreed to acquire Intercept for $19.00 per share in cash. The anticipated transaction will materially expand Alfasigma’s gastrointestinal and hepatology portfolio and its presence in the U.S. market.]]>https://www.globenewswire.com/news-release/2023/09/05/2737373/0/en/Intercept-Pharmaceuticals-to-Conduct-Fireside-Chats-and-One-on-One-Meetings-at-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=17531Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences2023-09-05T12:30:00Z<![CDATA[MORRISTOWN, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, and Andrew Saik, Chief Financial Officer of Intercept, will participate in fireside chats and investor meetings at the following upcoming investor conferences:]]>https://www.globenewswire.com/news-release/2023/08/02/2716673/0/en/Intercept-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html?f=22&fvtc=4&fvtv=17531Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates2023-08-02T11:00:00Z<![CDATA[MORRISTOWN, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced its financial results for the quarter ended on June 30, 2023.]]>https://www.globenewswire.com/news-release/2023/07/26/2711267/0/en/Intercept-to-Announce-Second-Quarter-2023-Financial-Results-on-August-2-2023.html?f=22&fvtc=4&fvtv=17531Intercept to Announce Second Quarter 2023 Financial Results on August 2, 20232023-07-26T12:00:00Z<![CDATA[MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial results on Wednesday, August 2, 2023. The announcement will be followed by a conference call and audio webcast at 8:30 a.m. ET.]]>https://www.globenewswire.com/news-release/2023/06/23/2693568/0/en/Intercept-Announces-Restructuring-to-Strengthen-Focus-on-Rare-and-Serious-Liver-Diseases-and-Significantly-Reduce-Operating-Expenses.html?f=22&fvtc=4&fvtv=17531Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses2023-06-23T10:30:00Z<![CDATA[MORRISTOWN, N.J., June 23, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced a restructuring to strengthen the Company’s focus on rare and serious liver diseases and significantly reduce operating expenses, including discontinuing all nonalcoholic steatohepatitis (NASH)-related investment.]]>https://www.globenewswire.com/news-release/2023/06/23/2693415/0/en/Intercept-Presents-New-Data-Showing-Significant-Impact-of-OCA-bezafibrate-Combination-on-Normalization-of-Multiple-Biomarkers-of-PBC-Induced-Liver-Damage.html?f=22&fvtc=4&fvtv=17531Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage2023-06-23T06:45:00Z<![CDATA[Planned interim analysis from the first of two Phase 2 studies shows combination of OCA 5-10 mg + bezafibrate 400 mg normalized a range of biomarkers of PBC (ALP, total bilirubin, GGT, ALT and AST) in 58% of patients at 12 weeks]]>